ReviewDrugs & aging2025
Optimizing Prevention of Recurrent Urinary Tract Infections in Older Patients with Frailty.
Review in Drugs & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty is associated with impaired immune function, functional decline, and increased vulnerability to both infection and adverse medication effects. Recurrent urinary tract infection (rUTI) is a common and burdensome condition among older persons, particularly those living with frailty. Despite this, frail individuals remain underrepresented in clinical research guiding rUTI prevention. This review outlines current evidence on rUTI prevention strategies in older persons living with frailty. It highlights feasible tools for frailty assessment and explores how frailty contributes to infection risk and impacts the effectiveness and safety of preventive interventions. Nonpharmacological strategies-including continence management, minimization of catheter use, hydration support, and carer education-form the foundation of prevention. Locally applied vaginal estrogen is the best-supported pharmacological option in postmenopausal women. Evidence for cranberry products, D-mannose, and probiotics remains inconsistent in frail populations, while methenamine hippurate offers a promising, well-tolerated alternative to antibiotics. Prophylactic antibiotic use may reduce recurrence in selected patients but carries significant risks, including Clostridioides difficile infection and antimicrobial resistance. Clinical decision-making should be guided by individualized risk assessment, careful consideration of treatment burden, and regular reassessment of both benefits and harms. Further research is urgently needed to inform evidence-based prevention strategies for this vulnerable population.
Indexed as
Identifiers
40665177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.